Advertisement

Iron regulation of dopaminergic transmission: relevance to movement disorders

  • D. Ben-Shachar
  • A. Tovi
  • M. B. H. Youdim
Conference paper
Part of the Key Topics in Brain Research book series (KEYTOPICS)

Summary

Dopamine has been implicated in many central and peripheral functions, among which are motor control, cognitive, affective and neuroendocrine functions. We suggest that iron plays a crucial role in the dopamine system, being essential for the normal functioning of several components in the metabolism and transmission of dopamine. In 6-hydroxydopamine treated rats, which serve as an animal model of Parkinson’s disease, chelation of iron by desferrioxamine retarded the degeneration, expressed both biochemically and behaviorally, of the nigrostriatal dopamine neurons. Moreover, introducing iron into the substantia nigra of the rat induced parkinsonian-like biochemical and behavioral responses. Long term neuroleptic treatment in schizophrenia, which is associated with extrapyramidal motor side effects, the most severe of which is tardive dyskinesia, caused in rats dopamine supersensitivity, which could be regulated by iron supplementation or deprivation. This was accompanied by a significant transport of iron into the brain which is normally very limited. In addition there was a definite correlation between the ability of the neuroleptic drug to induce iron transport into the brain and its ability to induce extrapyramidal severe motor side effects. The significance of brain iron homeostasis to dopamine normal motor and biochemical function in animal models is argued.

Keywords

Iron Deficiency Tardive Dyskinesia Dopaminergic Transmission Iron Regulation Nigrostriatal Dopamine Neuron 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bartzokis G, Garber HJ, Marder SR, Oldendorf WH (1990) MRI in tardive dyskinesia shortened left caudate T2. Biol Psychiatry 28: 1027–1036PubMedCrossRefGoogle Scholar
  2. Ben-Shachar D, Youdim MBH (1990) Neuroleptic-induced supersensitivity and brain iron: iron deficiency and neuroleptic-induced dopamine D2 receptor supersensitivity. J Neurochem 54: 1136–1141PubMedCrossRefGoogle Scholar
  3. Ben-Shachar D, Youdim MBH (1991) Intranigral iron injection induces behavio-ral and biochemical “parkinsonism” in rats. J Neurochem 57: 2133–2135PubMedCrossRefGoogle Scholar
  4. Ben-Shachar D, Finberg JPM, Youdim MBH (1985) Effect of iron chelators on dopamine D2 receptors. J Neurochem 45: 999–1005PubMedCrossRefGoogle Scholar
  5. Ben-Shachar D, Ashkenazi R, Youdim MBH (1986) Long term consequence of early iron deficiency on dopaminergic neurotransmission. Int J Dev Neurosci 4: 91–98CrossRefGoogle Scholar
  6. Ben-Shachar D, Pinhassi B, Youdim MBH (1991a) Prevention of neurolepticinduced dopamine D2 receptor supersensitivity by chronic iron salt treatment. Eur J Pharmacol 202: 177–183PubMedCrossRefGoogle Scholar
  7. Ben-Shachar D, Eshel G, Finberg JPM, Youdim MBH (1991b) The iron chelator desferrioxamine (desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J Neurochem 56: 1441–1444Google Scholar
  8. Campbell WG, Raskind MA, Gordon T, Shaw CM (1985) Iron pigment in the brain of man with tardive dyskinesia. Am J Psychiatry 142: 362–364Google Scholar
  9. Cohen G, Heikkila RE, McNamee D (1974) The generation of hydrogen peroxide, superoxide radicals and hydroxy radicals by 6-hydroxydopamine dialuric acid and related cytotoxic agents. J Biol Biochem 249: 2447–2459Google Scholar
  10. Csernansky JC, Holman CA, Bounet KA, Garabowsky K, King R, Hollister LE (1983) Dopaminergic supersensitivity at distant sites following induced epileptic foci. Life Sci 32: 385–390PubMedCrossRefGoogle Scholar
  11. Dallman PR, Spirito RAJ (1977) Brain iron in the rat: extremely slow turnover in normal rats may explain long lasting effects of early iron deficiency. Nutrition 107: 1075–1081Google Scholar
  12. Dexter DT, Wells FR, Lees AJ, Javoy-Agid F, Agid Y, Jenner P, Marsden CD (1989) Increased nigral iron content and alteration in other metal ions occurring in brain in Parkinson’s disease. J Neurochem 52: 1830–1836PubMedCrossRefGoogle Scholar
  13. Dwork AJ, Lawler G, Zybert PA, Durkin M, Osman M, Willson N, Barakai A (1990) An autoradiographic study of uptake and distribution of iron in the brain of young rat. Brain Res 518: 31–39PubMedCrossRefGoogle Scholar
  14. Graham D, Tiffany SM, Bell WR, Gutknecht WF (1978) Auto-oxidation versus covalent binding quinones as the mechanism of toxicity of dopamine, 6hydroxydopamine and related compounds towards C 1300 neuroblastoma cells in vitro. Mol Pharmacol 14: 644–653PubMedGoogle Scholar
  15. Hill JM, Switzer RC (1984) The regional distribution and cellular localization of iron in the rat brain. Neuroscience 11: 595–603PubMedCrossRefGoogle Scholar
  16. Hunter R, Blackwood W, Smith MCJ (1968) Neuropathological findings in three cases of persistent dyskinesia following phenothiazine medication. J Neurol Sci 7: 763–773CrossRefGoogle Scholar
  17. Klawans HL, (1973) The pharmacology of tardive dyskinesia. Am J Psychiatry 130: 82–86PubMedGoogle Scholar
  18. Monterio HP, Winterbourne CC (1989) 6-Hydroxydopamine releases iron from ferritin and promotes ferritin-dependent lipid peroxidation. Biochem Pharmacol 38: 4144–4182Google Scholar
  19. Moser A, Schuster O (1990) Iron inhibits dopamine Di receptor coupled adenylate cyclase via G-proteins in caudate nucleus of the rat. Biochem Biophys Res Commun 171: 1372–1377PubMedCrossRefGoogle Scholar
  20. Nagatsu T, Levitt M, Udenfriend S (1964) Tyrosine hydroxylase, the initial step in norepinephrine biosynthesis. J Biochem Chem 239: 2910–2917Google Scholar
  21. Nagatsu T, Levitt M, Udenfriend S (1964) Tyrosine hydroxylase, the initial step in norepinephrine biosynthesis. J Biochem Chem 239: 2910–2917Google Scholar
  22. Sofic E, Riederer P, Heinsen H, Youdim MBH (1988) Increased iron III and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm 74: 199–205PubMedCrossRefGoogle Scholar
  23. Spatz H (1992) Über den Eisennachweis im Gehirn, besonders in Zentren des extrapyramidal motorischen Systems. Z Ges Neurol Psychiatry 28: 261–390Google Scholar
  24. Stille G, Lauener H, Eichenberger E (1971) The pharmacology of 8-chloro-11-(4methyl-l-piperazinyl)-5H-dibenzo [b,e] [1,4] diazapine (clozapine). Il Pharmaco 26: 603–625Google Scholar
  25. Symes AL, Sourker TL Youdim MBH, Gregoriadis G, Birnbaum H (1969) Decreased monoamine oxidase activity in liver of iron deficient rats. Can J Biochem 47: 999–1002PubMedCrossRefGoogle Scholar
  26. Tovi A (1992) The effect of iron deficiency on the metabolism of neurotransmitters in the brain. Thesis, Technion, Haifa, IsraelGoogle Scholar
  27. Youdim MBH, Ben-Shachar D, Yehuda S (1989) Putative biological mechanism of the effect of iron deficiency on brain biochemistry and behaviour. Am J Nutr [Suppl] 50: 607–617Google Scholar

Copyright information

© Springer-Verlag/Wien 1993

Authors and Affiliations

  • D. Ben-Shachar
    • 2
  • A. Tovi
    • 1
  • M. B. H. Youdim
    • 1
  1. 1.Department of Pharmacology, Faculty of MedicineTechnionHaifaIsrael
  2. 2.Department of Pharmacology, Faculty of MedicineTechnionHaifaIsrael

Personalised recommendations